Monitoring of a heart hormone (NT-proBNP) in the dialysis population for the prediction of major cardiovascular events

Serial NT-proBNP Monitoring in the Dialysis Population for the Prediction of Major Cardiovascular Events

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12612000836831

Acronym

MONITOR - Monitoring Oscillations of NT-proBNP In guiding Therapy and predicting Outcomes in Renal d

Enrollment

150

Registered

2012-08-08

Start date

2011-06-06

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Compared with the general population, dialysis patients have a 100-fold increased risk of dying from heart disease which has remained unchanged over the last decade. The main factor which predicts this risk in dialysis patients is abnormal heart muscle structure and function. Excess body fluid and high blood pressure are critical risk factors leading to these heart abnormalities. Current tests to identify dialysis patients at high risk are quite inaccurate and optimum blood pressure/fluid targets remain undefined. There is an urgent need for a blood test that accurately detects the early stages of heart injury to enable effective treatments. NT-proBNP is a heart hormone released during heart stress and early studies suggest it can predict which dialysis patients do poorly. The aim of our research is to develop a monitoring guideline based on regular testing of NT-proBNP to identify high-risk dialysis patients early. This would enable treatment before a serious medical complication occurs, potentially improving patient outcomes on dialysis. We will achieve this by testing NT-proBNP monthly in a group of 150 dialysis patients for 2-years, and correlating changes in the hormone levels with changes in patient symptoms, their health, body fluid state, and heart structure and function.

Interventions

N-terminal pro B-type Natriuretic Peptide (NT-proBNP), Bioimpedance, Framingham Truncated Heart Failure Score - observed monthly for 24-months

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

In-centre haemo- or peritoneal dialysis patients established on dialysis for at least 90-days Established on a single dialysis modality for at least 30-days Aged 18-years or older Temporary or permanent vascular access Able to provide informed consent

Exclusion criteria

Advanced malignancy and/or current malignancy undergoing evaluation and/or treatment – excludes skin cancers Permanent pacemaker and/or implantable cardiac defibrillator Limb amputee Living donor renal transplant planned within 3-months of enrolment Home haemodialysis Congenital heart disease (excluding haemodynamically insignificant patent foramen ovale) Acute renal impairment with the expectation of spontaneous recovery of renal function Pregnancy

Outcome results